The blincyto market size is expected to see strong growth in the next few years. It will grow to $1,022.10 million in 2029 at a compound annual growth rate (CAGR) of 5.9%.” - The Business ...

Amgen’s Blincyto (blinatumomab) has been approved by the European Commission (EC) to treat certain acute lymphoblastic leukaemia (ALL) patients earlier in their treatment journey. Blincyto monotherapy ...

Experts say the kuranui, otherwise known as moa, played a vital part in sustaining rākau Māori, crucial to the wellbeing of the taiao and the Māori language. The kuranui, otherwise known as moa ...

Amgen’s Blincyto has been granted a full European licence in a form of blood cancer following data showing the drug almost doubled overall survival time compared with standard therapy.

A SEVENTEEN pop-up store has officiall opened at the Mall of Asia on Wednesday. But it's not just any SEVENTEEN pop-up store, it's an “Artist-Made Collection by SEVENTEEN” pop-up store. Located at the ...

Here’s how the weekend went globally and overseas. Lots to celebrate: Disney’s Mufasa: The Lion King is now the No. 9 global release of 2024 with $539.7M, including $350.9M from the ...

NEW YORK – The European Commission on Wednesday approved Amgen's bi-specific T-cell engager Blincyto (blinatumomab) as part of consolidation therapy for the treatment of adult patients with newly ...

The European Commission (EC) has approved Blincyto (blinatumomab) monotherapy as part of consolidation therapy for the treatment of adults with newly-diagnosed Philadelphia chromosome-negative ...